Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
In Vivo ; 34(3): 1533-1539, 2020.
Article in English | MEDLINE | ID: mdl-32354959

ABSTRACT

BACKGROUND/AIM: Lymphovascular invasion (LVI) is recognized as a prognostic predictor of recurrence in certain carcinomas. According to current Japanese guidelines, however, in gastric cancer, LVI is not clinically useful information, except for predicting the curability of endoscopic resection. We clarified the clinical significance of LVI in gastric cancer and its correlation with disease prognosis. PATIENTS AND METHODS: A total of 2,090 cases of gastric cancer undergoing radical gastrectomy were enrolled. The correlation of LVI and other histopathological factors was evaluated with regards to patient prognosis. RESULTS: LVI(+) was noted in 894 cases. A multivariate analysis showed that pT, pN, and LVI were independent risk factors for patient prognosis. In pT2-4 patients with nodal metastasis, a significant difference was revealed, and the 5-year overall survival rates in LVI(+) cases were lower than those in LVI(-) (60.9% vs. 76.7%, p=0.005). CONCLUSION: LVI in gastric cancer is an independent prognostic factor, and tends to worsen prognosis, especially in advanced cancers with lymph node metastases.


Subject(s)
Stomach Neoplasms/pathology , Aged , Aged, 80 and over , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Grading , Neoplasm Invasiveness , Neoplasm Staging , Prognosis , Stomach Neoplasms/mortality , Stomach Neoplasms/therapy , Tumor Burden
2.
Anticancer Res ; 26(3B): 2221-6, 2006.
Article in English | MEDLINE | ID: mdl-16821591

ABSTRACT

BACKGROUND: To find a way to prevent the development of hepatocellular carcinoma (HCC) from hepatitis C virus-associated liver cirrhosis (HCV-LC), an analysis of the HCV-LC patients who had received reduction therapy of the alanine aminotransferase (ALT) levels was performed. PATIENTS AND METHODS: Seventy-four consecutive HCV-LC patients of Child Stage A were followed for >10 years for the development of HCC. They were divided into two groups: in group A, the reduction therapy for the ALT levels was aggressively performed, while in group B, the reduction therapy was not performed aggressively. The patients were subdivided into three sub-groups according to their serum ALT levels. In groups A and B, the high ALT group was comprised, respectively, of nine and five patients whose annual average serum ALT levels were persistently high (> or =80 IU), while the low ALT group was comprised of 19 and 20 patients whose annual average serum ALT levels were persistently low (<80 IU). The remaining eleven and ten patients had annual average serum ALT levels which fluctuated and were unclassified (unclassified group). RESULTS: In group B, 65.7% of the patients had developed HCC in 13 years, in contrast to only 41.0% of group A (p=0.039). In group A, the median HCC development time was 12.8 years, in contrast to only 3.8 years in group B (p=0.0013). Multivariate analysis demonstrated that the mode of reduction therapy and ALT levels were the significant factors affecting HCC development. CONCLUSION: The chances of surviving for more than ten years without developing HCC for HCV-LC patients


Subject(s)
Alanine Transaminase/blood , Carcinoma, Hepatocellular/prevention & control , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/enzymology , Liver Cirrhosis/drug therapy , Liver Cirrhosis/enzymology , Liver Neoplasms/prevention & control , Carcinoma, Hepatocellular/enzymology , Carcinoma, Hepatocellular/virology , Drugs, Chinese Herbal/therapeutic use , Female , Glycyrrhizic Acid/therapeutic use , Hepacivirus , Hepatitis C, Chronic/complications , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/virology , Liver Neoplasms/enzymology , Liver Neoplasms/virology , Male , Middle Aged , Protoporphyrins/therapeutic use , Retrospective Studies , Ursodeoxycholic Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...